Document:

Exhibit 10.29

Exhibit 10.29

2011 COMPENSATION INFORMATION FOR REGISTRANT’S EXECUTIVE OFFICERS

The table below provides information regarding (i) the base salary of each executive officer
of GTx, Inc. (the “Company”), effective as of
January 1, 2011 (except as noted), and (ii) the target cash bonus award
for Fiscal 2011 for each of the Company’s executive officers under the Company’s Executive Bonus
Compensation Plan, expressed as a percentage of applicable base salary:

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 		 	 	2011	 
	 	 	 	 	2011	 	 	Target	 
	 	 	 	 	Annual	 	 	Bonus (%	 
	Executive Officer	 	Title	 	Salary ($)	 	 	of Salary)	 
	Mitchell S. Steiner
	 	Chief Executive Officer and Vice-Chairman of the Board of Directors	 	 	525,000	 	 	 	65	 
	Marc S. Hanover
	 	President and Chief Operating Officer	 	 	456,750	 	 	 	55	 
	Ronald A. Morton, Jr.
	 	Vice President, Chief Medical Officer	 	 	452,025	(1)	 	 	30	 
	James T. Dalton
	 	Vice President, Chief Scientific Officer	 	 	400,000	 	 	 	30	 
	Henry P. Doggrell
	 	Vice President, General Counsel and Secretary	 	 	351,281	(2)	 	 	30	 
	Mark E. Mosteller
	 	Vice President, Chief Financial Officer and Treasurer	 	 	298,083	 	 	 	30	 

	 	 	 
	(1)	 	Dr. Morton will also be eligible for tax gross-up payments related to certain
travel expenses paid by the Company during 2011 on his behalf.
	 
	(2)	 	Effective as of February 21, 2011.Exhibit 10.50

Exhibit 10.50

Non-Employee Director Compensation Policy of GTx, Inc.

Effective Date: 2/18/2011

I. Purpose

This Policy sets forth guidelines pertaining to compensation for non-employee Directors of the GTx,
Inc. Board of Directors (“Board”).

II. Scope

This Policy applies to all non-employee members of the Board and is not applicable to employee
members of the Board. This Policy shall remain in effect until it is revised or rescinded by
further action of the Board.

III. Policy Statements

The Board sets non-employee Directors’ compensation at the recommendation of the Nominating and
Corporate Governance Committee and the Compensation Committee. Compensation for non-employee
Directors is comprised of a mix of cash and equity-based compensation.

Periodically, at the direction of the Nominating and Corporate Governance Committee, the Company
provides information from independent consultants and/or data management sources relating to Board
compensation paid by companies comparable to the Company within the biotech and pharmaceutical
industries. The Nominating and Corporate Governance Committee uses this information in making its
recommendations to the Compensation Committee regarding any modifications to Board compensation.
The Compensation Committee considers the information and recommendations provided by the Nominating
and Corporate Governance Committee and makes its recommendations to the Board. The Board then sets
the Directors’ compensation taking into account the recommendations from the Committees. Cash
compensation payments and equity awards shall be paid or be made, as applicable, automatically and
without further action of the Board, unless such non-employee Director declines to receive such
compensation or awards by written notice to the Company.

A. Cash Compensation 

Annual Retainer

Each non-employee Director shall be eligible to receive an annual retainer of $25,000, except the
Chairman of the Audit Committee who shall receive an annual retainer of $35,000 for services on the
Board. The annual retainer will be paid in quarterly installments, on or about the first day of
each quarterly period.

Meeting Stipends

Each non-employee Director shall receive a stipend of $2,000 for every regularly scheduled (or
special) meeting of the Board and its committees physically attended by such Director and a $750
stipend for each telephonic meeting in which the Director participated, payable after the end of
each calendar quarter.

			
	 	 	 
	Director Compensation Policy
	 	Page 1 of 3

 

 

 

Expense Reimbursement

The Company shall reimburse a non-employee Director for all of his or her reasonable expenses
incurred to attend meetings of the Board or its committees. Any travel expenses shall be reimbursed
in accordance with the Company’s standard travel policy. The travel expenses will be reimbursed
within thirty (30) days after receipt by the Company of an invoice together with originals or
copies of receipts showing the payment of such expenses.

B. Directors’ Deferred Compensation 

Each non-employee Director has the opportunity to defer all or a portion of his or her cash
compensation under the Company’s Directors’ Deferred Compensation Plan. Deferrals can be made into
a cash account, a stock unit account, or a combination of both. All distributions under the
Directors’ Deferred Compensation Plan will be made in the form of a single lump sum in cash (for
amounts credited to cash accounts) or in shares of GTx common stock (for amounts credited to stock
unit accounts), except that any fractional shares of GTx common stock will be distributed in cash
valued at the then current fair market value of GTx common stock, all of which is more particularly
set forth in the Directors’ Deferred Compensation Plan.

C. Equity-Based Compensation 

The Company’s 2004 Non-Employee Directors’ Stock Option Plan, as amended, provides for the
automatic grant of initial and annual nonstatutory stock options to GTx’s non-employee Directors
who do not own more than ten percent of the combined voting power of GTx’s then outstanding
securities.

Initial Award

Pursuant to the 2004 Non-Employee Directors’ Stock Option Plan, as amended, any individual who
first becomes a non-employee Director automatically is granted an option to purchase shares of GTx
common stock. The number of shares subject to each of these initial option grants is 15,000 shares,
provided that the number of options may be increased or decreased by the Board in its sole
discretion.

Annual Awards

Any individual who is serving as a non-employee Director on the day following an annual meeting of
GTx’s stockholders automatically will be granted an option to purchase shares of common stock on
that date; provided, however, that if the individual has not been serving as a non-employee
director for the entire period since the preceding annual meeting, the number of shares subject to
such individual’s annual grant will be reduced pro rata for each full month prior to the date of
grant during which such individual did not serve as a non-employee Director. The number of shares
subject to each annual option grant is 15,000 shares, provided that the number of options may be
increased or decreased by the Board in its sole discretion.

Provisions Applicable to All Non-Employee Director Awards

The exercise price per share for the options granted under the 2004 Non-Employee Directors’ Stock
Option Plan, as amended, is not less than the fair market value of the Company’s common stock on
the date of grant. The options which are the subject of an initial grant and an annual grant will
vest in a series of three successive equal annual installments measured from the date of grant, so
that each initial grant of options and each annual grant will be fully vested three years after the
date of grant.

In the event of specified corporate transactions, as defined in the 2004 Non-Employee Directors’
Stock Option Plan, as amended, all outstanding options under the 2004 Non-Employee Directors’ Stock
Option Plan, as amended, may be assumed or substituted for by any surviving or acquiring entity. If
the surviving or acquiring entity elects not to assume or substitute for such options, then (a)
with respect to any such options that are held by optionees then performing services for GTx
or its affiliates, the vesting and exercise of such options will be accelerated in full and such
options will be terminated if not exercised prior to the effective date of the corporate
transaction, and (b) all other outstanding options will terminate if not exercised prior to the
effective date of the corporate transaction.

			
	 	 	 
	Director Compensation Policy
	 	Page 2 of 3

 

 

 

If a specified “change of control” transaction occurs, as defined in the 2004 Non-Employee
Directors’ Stock Option Plan, as amended, then the vesting and exercise of the optionee’s options
will be accelerated in full immediately prior to (and contingent upon) the effectiveness of the
transaction. If an optionee is required to resign his or her position as a non-employee Director as
a condition of the transaction, the vesting and exercise of the optionee’s options will be
accelerated in full immediately prior to the effectiveness of such resignation.

IV. Related Documents / Information

A. Directors’ Deferred Compensation Plan

B. 2004 Non-Employee Directors’ Stock Option Plan (Amended)

C. Finance Policy, Business Travel and Expense

V. Policy Owner

For assistance with interpretation regarding this policy, or any questions relating to this policy,
contact:

Henry P. Doggrell

VP, General Counsel

(901) 507-6916

hdoggrell@gtxinc.com

VI. Revision History

Original Policy — Effective 1/1/2009

(Adopted by the GTx, Inc. Compensation Committee of the Board of Directors on 11/4/2008)

VII. Approval

The signature below indicates that this policy has been approved by the Finance Department as of
the approval date set forth below.

	 	 	 
	/s/ Henry P. Doggrell

	 	February 28, 2011
	 

	 	 
	Henry P. Doggrell

	 	Date
	Vice President, General CounselExhibit 10.58

Exhibit 10.58

25 February 2011

Dr. Mitchell S. Steiner

Chief Executive Officer

GTx, Inc.

175 Toyota Plaza, 7th Floor

Memphis, Tennessee 38103

U.S.A

By email-and UPS

	 	 	 
	Re:

	 	Mutually agreed termination of the Toremifene Collaboration and License Agreement dated 7
September 2006 as amended by First Amendment dated 22 March 2010

Dear Mitch:

We refer to the Collaboration and License Agreement dated 7 September 2006 (as amended, the
“Agreement”) between GTx, Inc. (“GTx”) and Ipsen Limited (n/k/a Ipsen Biopharm
Limited) (“Ipsen” and, together with GTx, the “Parties”), as amended by the First
Amendment dated 22 March 2010 (“Amendment”).

This Letter Agreement formalizes the mutually agreed decision made by Ipsen and GTx based on
the discussions held in New York on 21 February 2011 among the Parties’ representatives,
specifically Dr. Mitchell Steiner, Marc Hanover, Henry Doggrell and David Levinson of GTx, and
Stéphane Thiroloix, Sean McKercher, Vanessa Malier and Toshiki Enomoto of Ipsen as follows:

	 	1.	 	Subject to approval of Ipsen’s board of directors which Ipsen shall notify to
GTx on or before 1 March 2011 5:00 pm US EST, the Agreement and the Amendment are
hereby terminated by mutual agreement of the Parties as of 1 March 2011, except as
provided at Sections 2 to 6 below.
	 
	 	2.	 	In consideration of Ipsen’s agreement to terminate its rights and obligations
in the Ipsen Territory except as provided herein, including its rights to Right of
First Negotiation to GTx-758, GTx agrees to pay to Ipsen running royalty payments in US
dollars on US Net Sales of the Licensed Product for the ADT Indication in the amount of
3% until the later to occur of (a) the last Valid Patent Claim to expire in the US or
(b) if the expiry of a Valid Patent Claim occurs earlier than 30 November 2022 as a
result of a third party claim which shall lead to generic market penetration in the US
by more than 20% for a period of two (2) consecutive quarters, then at the end of that
second quarter. The US Royalty Payment due to Ipsen on account of US Net Sales shall
be payable by GTx to Ipsen within 60 days of the end of each Calendar Quarter for which
royalty payments are owed, accompanied by a quarterly report providing in reasonable
detail in quantity and value an accounting of the US Net Sales made during such
Calendar Quarter. Furthermore, Article 11.4 of the Agreement (i.e., records and audit
rights) shall apply mutatis mutandis to Ipsen’s right to verify the accuracy of GTx’s
reports for the calculation of US Net Sales of the Licensed Product for the ADT
Indication.
	 
	 	3.	 	Except as provided herein, no party shall be entitled to receive any
compensation whatsoever as a consequence of such mutual termination.

 

 

 

	 	4.	 	Except as provided herein, Ipsen and GTx shall be fully and entirely discharged
from any and all of their respective obligations under the Agreement and the Amendment
and shall have no liability relating thereto, except for all obligations set forth in
Article XIII “Indemnification,” Article XIV “Dispute Resolution,” and Articles 15.4
through 15.13 which shall survive this mutual termination and remain binding upon Ipsen
and GTx as applicable to this Letter Agreement until the expiry of the term mentioned
at Section 2 above and Article VIII “Confidentiality”, which shall survive this mutual
termination and remain binding upon Ipsen and GTx for the time-period mentioned in such
provision, provided that, the Parties agree that notwithstanding the provisions of
Section 8.4 of the Agreement, GTx shall not be required to provide to Ipsen for prior
review and approval “any proposed scientific/technical publications or scientific
presentations which relate to Toremifene and/or Licensed Product” as otherwise required
under Section 8.4.
	 
	 	5.	 	The Parties hereby agree that the Parties shall issue a press release relating
to this mutual termination of the Agreement and the Amendment on 2 March 2011. Working
draft of press releases concerning this mutual termination shall be provided to Ipsen
or GTx by the originator of the release no later than 25 February 2011 5:00 pm US EST
for the other party’s written approval, which shall not unreasonably be withheld or
delayed, except to the extent required by applicable laws or stock exchange rules.

All capitalized terms used in this Letter Agreement without definition have the respective
meanings provided in the Agreement and the Amendment.

Please confirm your agreement to this mutual termination by returning to us a countersigned
copy of this letter.

This Letter Agreement takes effect as of the date first above written.

Yours sincerely,

	 	 	 
	/s/ Stéphane Thiroloix
	 	 
	 

Stéphane Thiroloix

	 	 
	Executive Vice President, Corporate Development
	 	 

	 	 	 	 	 
	 	Acknowledged and agreed as of February 28, 2011

GTx, Inc.

 	 
	 	/s/ Mitchell S. Steiner
 	 

Cc: GTx, Inc. (Vice President, General Counsel and Secretary)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]